Sino Biopharmaceutical
Sino Biopharmaceutical Limited, commonly referred to as Sino Biopharm, is a leading player in the pharmaceutical industry, headquartered in Hong Kong. Founded in 1997, the company has established a strong presence across major operational regions, including Mainland China and various international markets. Sino Biopharm focuses on the research, development, manufacturing, and marketing of innovative medicines, particularly in the fields of oncology, cardiovascular diseases, and infectious diseases.
With a robust portfolio of core products, Sino Biopharm distinguishes itself through its commitment to high-quality standards and advanced biopharmaceutical technologies. The company has achieved significant milestones, including numerous product approvals and a growing market share, positioning itself as a key contributor to the healthcare landscape. Notably, Sino Biopharm's dedication to innovation and patient-centric solutions has earned it recognition as a trusted name in the biopharmaceutical sector.
-11 vs industry average
Sino Biopharmaceutical’s score of 27 is lower than 42% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Sino Biopharmaceutical?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Sino Biopharmaceutical's reported carbon emissions
Sino Biopharmaceutical, headquartered in Hong Kong, reported approximately 208,220,000 kg CO2e in total emissions for 2024. This figure encompasses Scope 1 and Scope 2 emissions, totalling 18,238,620 kg CO2e and 189,981,390 kg CO2e respectively. For the preceding year, 2023, total emissions were approximately 239,239,610 kg CO2e, comprising Scope 1 emissions of 17,046,220 kg CO2e and Scope 2 emissions of 222,193,400 kg CO2e. In 2022, the company's total emissions stood at approximately 277,084,360 kg CO2e, with Scope 1 at 16,093,260 kg CO2e and Scope 2 at 260,991,100 kg CO2e. The company aims to reduce its GHG emissions per RMB1 million of revenue by 20% by 2025, using 2021 as the benchmark year. This is a near-term intensity target covering all scopes. Sino Biopharmaceutical has not disclosed Scope 3 emissions data in its recent reporting.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Sino Biopharmaceutical’s Climate Goals (2030 & 2050)
1 goal2025
20% reduction in all scopes
Reduce GHG emissions per RMB1 million of revenue by 2025 with 2021 as the year of benchmark
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 1 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Sino Biopharmaceutical
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project